For research use only. Not for therapeutic Use.
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2−/− knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP)[1].
Asfotase alfa (0.5-8.2 mg/kg; s.c. once daily for 43 days) shows dose-response relationships that strongly support the pharmacological efficacy for HPP[1].
Catalog Number | I042680 |
CAS Number | 1174277-80-5 |
Purity | ≥95% |
Reference | [1]. Yadav MC, et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone. 2011 Aug;49(2):250-6. |